Physician profile
Jonathan D Copeland
NPI 1730393448
$9,511.75
in general payments reported to CMS, 2019-2025
43 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,229 · 2021: $1,370 · 2022: $1,253 · 2023: $1,681 · 2024: $1,624 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,460.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,320.29 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,193.12 | 2019-2025 | |
| Abbvie INC. | $948.18 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $940.95 | 2019-2025 | Airsupra, Farxiga, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.92 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $368.76 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $292.14 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Amgen INC. | $252.99 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $189.03 | 2019-2025 | Eohilia |
| Abbott Laboratories | $187.04 | 2020-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Gilead Sciences, INC. | $184.31 | 2021-2023 | |
| Astellas Pharma US INC | $177.91 | 2023-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $173.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $112.77 | 2022-2025 | Spravato |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.